Thursz, M.R. (Mark R.)

Filtering

2019 - 20202

Settings

Author search.filters.isAuthorOfPublication.820ae838-e8ac-4ee5-ab72-59a26d682a3c

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Recent advances in alcohol-related liver disease (ALD): summary of a Gut roundtable meeting
    (2020) Poznyak, V. (Vladimir); Burra, P. (Patrizia); Thursz, M.R. (Mark R.); Avila, M.A. (Matías Antonio); Zoulim, F. (Fabien); Dufour, J.F. (Jean-Francois); Cortez-Pinto, H. (Helena); Schnabl, B. (Bernd); Gao, B. (Bin); Thiele, M. (Maja); Bataller, R. (Ramón); Moreno, C. (Christophe); Szabo, G. (Gyongyi); Gerbes, A. (Alexander); Mathurin, P. (Philippe); Gilmore, I. (Ian)
    Alcohol-related liver disease (ALD), which includes a range of disorders of different severity and is one of the most prevalent types of liver disease worldwide, has recently regained increased attention. Among other reasons, the realisation that any alcohol intake, regardless of type of beverage represents a health risk, and the new therapeutic strategies tested in recently published or undergoing clinical trials spur scientific interest in this area. In April 2019, Gut convened a round table panel of experts during the European Association for the Study of the Liver (EASL) International Liver Congress (ILC) in Vienna to discuss critical and up-to-date issues and clinical trial data regarding ALD, its epidemiology, diagnosis, management, pathomechanisms, possible future treatments and prevention. This paper summarises the discussion and its conclusions.
  • Thumbnail Image
    Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis
    (Springer Science and Business Media LLC, 2019) Latasa, M.U. (María Ujué); Blokhin, I.O. (Ilya O.); Monga, S.P. (Satdarshan P.); Dubuquoy, L. (Laurent); Berasain, C. (Carmen); Lozano, J.J. (Juan J.); Morgan, M.Y. (Marsha Y.); Vernetti, L.A. (Lawrence A.); Sancho-Bru, P. (Pau); Altamirano, J. (Jose); Wahlestedt, C. (Claes); Fondevilla, C. (Constantino); Gómez, J.L. (Juan L.); Arab, J.P. (Juan P.); Thursz, M.R. (Mark R.); Cao, S. (Sheng); Avila, M.A. (Matías Antonio); Atkinson, S.R. (Stephen R.); Rusyn, I. (Ivan); Edmunds, L.R. (Lia R.); Cabezas, J. (Joaquín); Furuya, S. (Shinji); Bell, A. (Aaron); Aragón, T. (Tomás); Mann, J. (Jelena); Shah, V.H. (Vijay H.); Jurczak, M.J. (Michael J.); Louvet, A. (Alexandre); Taylor, D.L. (D. Lansing); Lackner, C. (Carolin); Bataller, R. (Ramón); Odena, G. (Gemma); Caballeria, J. (Juan); Stärkel, P. (Peter); Gue, J.P. (Joel P.); Ventura-Cots, M. (Meritxell); Argemí, J. (Josepmaria); Mathurin, P. (Philippe); Massey, V. (Veronica); Van-Booven, D. (Derek)
    Alcoholic hepatitis (AH) is a life-threatening condition characterized by profound hepatocellular dysfunction for which targeted treatments are urgently needed. Identification of molecular drivers is hampered by the lack of suitable animal models. By performing RNA sequencing in livers from patients with different phenotypes of alcohol-related liver disease (ALD), we show that development of AH is characterized by defective activity of liver-enriched transcription factors (LETFs). TGFβ1 is a key upstream transcriptome regulator in AH and induces the use of HNF4α P2 promoter in hepatocytes, which results in defective metabolic and synthetic functions. Gene polymorphisms in LETFs including HNF4α are not associated with the development of AH. In contrast, epigenetic studies show that AH livers have profound changes in DNA methylation state and chromatin remodeling, affecting HNF4α-dependent gene expression. We conclude that targeting TGFβ1 and epigenetic drivers that modulate HNF4α-dependent gene expression could be beneficial to improve hepatocellular function in patients with AH.